Interatrial Shunt Therapy in Heart Failure Management

Interatrial shunt therapy represents an innovative device-based approach to alleviating elevated left atrial pressure in patients with heart failure, particularly those with preserved ejection fraction. By creating a controlled communication between the left and right atria, these shunts facilitate left-to-right blood flow, thereby reducing pulmonary congestion and improving exercise tolerance. Early clinical experience has demonstrated symptomatic relief and haemodynamic benefit, while ongoing device iterations seek to optimise shunt size, patency and safety. Approaches range from permanently implanted stents to novel no-implant techniques that use energy-based tissue excision. As the heart failure population becomes increasingly dominated by those with preserved systolic function and diastolic impairment, interatrial shunting has emerged as a key strategy alongside pharmacological and mechanical support therapies.

Research from Nature Portfolio

Recent computational and experimental modelling has provided insight into the comparative haemodynamic effects of interatrial shunts and mechanical support devices in heart failure with preserved ejection fraction. Patient-specific lumped-parameter simulations indicate that shunt devices substantially lower left atrial pressure at rest and during exertion, although they may modestly reduce cardiac output by redirecting flow. In contrast, mechanical assist pumps increase output but carry risks of suction events or vascular complications. These findings highlight the need for individualised therapy selection based on underlying cardiac reserve and the balance between pressure unloading and flow preservation.

Interatrial Shunt Therapy in Heart Failure Management publication trend

The graph below shows the total number of articles in interatrial shunt therapy in heart failure management across all publications each year (not limited to Nature Index journals).

Technical terms

Interatrial shunt: A surgically or percutaneously created communication between the left and right atria that permits controlled left-to-right blood flow to reduce left atrial pressure.

Heart failure with preserved ejection fraction (HFpEF): A form of heart failure characterised by symptoms of congestion despite a normal or near-normal left ventricular ejection fraction, primarily due to impaired ventricular relaxation and compliance.

Ejection fraction: The percentage of blood ejected from the left ventricle during systole, used as an index of systolic function.

Transcatheter: A minimally invasive delivery approach in which devices are introduced into the heart via vascular access, typically under imaging guidance.

Radiofrequency energy: High-frequency alternating current used to ablate or excise tissue, here applied to create a precise atrial septal fenestration without implanting a device.

References

1. Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine (2019).
2. Feasibility of a No-Implant Approach to Interatrial Shunts: Preclinical and Early Clinical Studies. Structural Heart (2022).
3. Device therapy with interatrial shunt devices for heart failure with preserved ejection fraction. Heart Failure Reviews (2022).
4. Comparison of device-based therapy options for heart failure with preserved ejection fraction: a simulation study. Scientific Reports (2022).